TNFa is a pleiotropic cytokine that signals for both survival and apoptotic cell fates. It is still unclear that the dual role of TNFa can be regulated in cancer cells. We previously described an apoptotic pathway involving p53!CDIP!TNFa that was activated in response to genotoxic stress. This pathway operated in the presence of JNK activation; therefore, we postulated that CDIP itself could sensitize cells to a TNFa apoptotic cell fate, survival, or death. We show that CDIP mediates sensitivity to TNFa-induced apoptosis and that cancer cells with endogenous CDIP expression are inherently sensitive to the growth-suppressive effects of TNFa in vitro and in vivo. Thus, CDIP expression correlates with sensitivity of cancer cells with TNFa, and CDIP seems to be a regulator of the p53-mediated death versus survival response of cells to TNFa. This CDIP-mediated sensitivity to TNFainduced apoptosis favors pro-over antiapoptotic program in cancer cells, and CDIP may serve as a predictive biomarker for such sensitivity. Cancer Res; 72(9); 2373-82. Ó2012 AACR.
Introduction
Two pathways of apoptosis have been described for mammalian cells: the intrinsic mitochondrial pathway, activated in response to cellular stress, and the extrinsic death receptor pathway, activated at the cell surface by the binding of TNFa family cytokines to their cognate receptors (1) (2) (3) (4) (5) (6) (7) . TNFa, however, can exert pleiotropic cellular effects, controlling cell proliferation, differentiation, and apoptosis, as well as regulating the host immune response (4-7).
TNFa does not generally induce apoptosis unless the NF-kB survival arm of the signal is inhibited (e.g., by blocking de novo protein synthesis with cycloheximide). However, any perturbation of the TNFa!NF-kB signal would be expected to produce a cellular outcome equivalent to that of blocking protein synthesis, resulting in apoptosis rather than survival in response to TNFa. Among transcription factors, the contribution of NF-kB and p53 to cancer development and progression as well as resistance to chemotherapy is well established (8) (9) (10) . Considering the deregulation of these 2 important factors in cancers, defining the cross-talk between NF-kB and p53 has been studied intensively for the molecular details and biologic outcome of their interaction (8) (9) (10) (11) . There are many places for intersection and cross-talk between the p53 and NF-kB pathways, which represent ways that NF-kB can regulate p53 and vice versa (12) .
Recently, we identified a novel p53 target, CDIP, and showed that CDIP acts in a hitherto unknown apoptotic pathway involving p53!CDIP!TNFa, acting in certain cells in response to DNA damage (13) . These findings were particularly intriguing given that in our cell systems NF-kB was not blocked, but cells nevertheless underwent apoptosis in a TNFa-and caspase 8-dependent manner. This raised the question of what was directing these cells to undergo TNFa-induced apoptosis. We hypothesized that CDIP itself could act as a sensitizing factor for a TNFa apoptotic cell fate.
Here we show that TNFa-induced apoptosis is dependent upon CDIP and that endogenous CDIP expression in cancer cells correlates with sensitivity to the death effects of TNFa. Importantly, the proapoptotic effect of CDIP!TNFa, which has previously been shown to be blocked by knockdown of endogenous TNFa, is rescued by the addition of human recombinant TNFa only in CDIP expressing cells. CDIP-dependent sensitivity to TNFa-induced apoptosis is further shown to be dependent upon JNK and occurs through a mechanism that involves an alteration in the NF-kB transcriptional program that favors proapoptotic over prosurvival gene expression. Overall, the identification of CDIP as an important sensitizing factor to TNFa-induced apoptosis has implications for TNFabased cancer therapeutics, as well as autoimmune diseases resulting from excessive TNFa signaling.
Materials and Methods
Cell lines and culture conditions U2OS, U2OS-CDIP (tet-on), IMR90-E1A, EJ, EJ-p53 (tet-off), A549, HT-1080, ME-180, A172, BT474, Calu3, LS174T, SW480, HCT116, MDAMB468, SKBR3, HCT1937, MDAMB435, H1975,  AU565, SUM149, WiDr, SNU1040, T24 , and RD cells were cultured in standard Dulbecco's modified Eagle's medium (Lonza) containing 10% FBS (Invitrogen), 100 U/mL penicillin, and 100 mg/mL streptomycin at 37
C. All these cell lines were obtained from the American Type Culture Collection. The cells were periodically authenticated by morphologic inspection and tested Mycoplasma contamination by PCR test (MycoSensor QPCR kit; Agilent Technologies Inc.,) every 6 months. In addition, cell line authentication was done before the initiation of the study by evaluating the presence of gene mutations (i.e., p53, Ras, and others) and specific gene expression via Q-PCR. EJ-p53 cells were additionally maintained in the presence of tetracycline (1 mg/mL), except for conditions of p53 induction. CDIP expression was induced in U2OS-CDIP cells by the addition of doxycycline to a final concentration of 1 mg/mL. Camptothecin (25 mmol/L) and etoposide (100 mmol/L) were solubilized in dimethyl sulfoxide (DMSO) and maintained at stock concentrations at À20
C and used at the concentrations indicated (Sigma-Aldrich). SP600125 (SP) JNK inhibitor (Calbiochem) was solubilized in DMSO, maintained at a stock concentration (50 mmol/L, À20 C), and used at a final concentration of 5 mmol/L. N-Acetyl-L-Cysteine (NAC) was solubilized in PBS, maintained at a stock concentration (1 mol/L, À20 C), and used at final concentrations of 1 to 40 mmol/L.
Cell death assays
Cell viability was determined by crystal violet staining (0.2% w/v in 2% ethanol) and Trypan blue exclusion (GIBCOInvitrogen). Apoptotic cell populations were determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (Roche). Briefly, cells were trypsinized, recovered by centrifugation at 300 Â g, and fixed in 2% paraformaldehyde-PBS for 16 hours. Cells were then washed twice with PBS and resuspended in fresh permeabilization solution (0.1% Triton-X 100 and 0.1% Sodium citrate) for 30 minutes at room temperature. Enzymatic labeling of free 3 0 -OH DNA ends with dUTP-conjugated to TMR red was carried out according to the manufacturer's protocol. The percentage of TUNEL-positive apoptotic cells was determined by flow cytometry enumeration of fluorescent cells (FL2-H: 570-620 nm).
Plasmids and siRNAs
The CDIP coding sequence based on DQ167023 was tagged with hemagglutinin and expressed in pcDNA3.1. We used validated CDIP siRNA oligonucleotides (Origene Trilencer-27 Human siRNA pool SR309314) to knock down the expression of endogenous CDIP as compared with cells transfected scrambled negative control siRNA duplex (Origene Trilencer-27 Universal Scrambled Negative Control siRNA Duplex SR30004). To exclude off-target effects of the siRNA, we used the 3 unique 27mer CDIP siRNA duplexes separately and in pool, all of which reduced CDIP expression (data not shown). Transfection conditions and vectors expressing control luciferase shRNA and shRNAs directed against CDIP and TNFa were previously described (13) .
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Results

CDIP expression sensitizes cells to recombinant TNFainduced cell death
Previous studies showed that in response to genotoxic stress, TNFa plays an essential role in CDIP-induced apoptosis (13) . If CDIP acts as a sensitizing factor for recombinant/ exogenous TNFa-induced cell death, then we would expect that the treatment of these cells with exogenous recombinant human TNFa (rhTNFa), without concomitant CDIP induction, would produce a cell survival rather than cell death effect. Indeed, in cells grown under normal conditions, in the absence of any p53!CDIP stress signal, rhTNFa has no effect on cell viability (Fig. 1A) . To directly test whether CDIP plays a role as a TNFa sensitizing factor, we disabled the endogenous CDIP!TNFa pathway by siRNA-directed knockdown of TNFa. As expected, this lead to increased long-term viability of CDIP-expressing U2OS-CDIP "tet-on" cells in response to doxycycline treatment and of IMR90-E1A cells exposed to camptothecin, which activates the p53!CDIP!TNFa pathway. However, the addition of rhTNFa to the culture was able to rescue the cell death effects of CDIP, with no apparent effect on cells lacking CDIP induction (Fig. 1B and C) . We then used TUNEL assay to evaluate whether these effects on cell viability were due to apoptosis and found that the addition of rhTNFa is able to promote apoptosis, only in CDIP expressing cells (Fig. 1B  and C) .
To further substantiate these findings, we titrated down the endogenous CDIP!TNFa signal and then tested whether exogenous rhTNFa could still rescue CDIP-dependent apoptosis in TNFa-shRNA expressing cells. The expression of TNFa transcript and TNFa-induced signaling, observed as I-kB phosphorylation, correlates with CDIP protein expression in a dose-dependent manner in both U2OS-CDIP "tet-on" and IMR90-E1A cells (Supplementary Fig. S1A and B). CDIPdependent apoptosis also showed a dose-dependent decrease as we decreased the concentration of doxycycline, indicating that we could control this cellular response by varying the amount of CDIP expressed ( Supplementary Fig.  S1C ). Again, the addition of rhTNFa to the culture rescued the attenuated apoptotic response of cells lacking endogenous TNFa (i.e., TNFa-siRNA transfected). Importantly, the rescue effect of rhTNFa was diminished as CDIP expression was decreased, showing that CDIP is required for TNFainduced apoptosis. If CDIP was not involved in this response, we would expect the levels of apoptosis in rhTNFa-rescued cells to remain the same regardless of any decrease in CDIP expression ( Supplementary Fig. S1C , dashed line). We next confirmed these findings in IMR90-E1A cells, in which the CDIP!TNFa pathway acts to induce apoptosis in response to genotoxic stress. The ability of exogenously added rhTNFa to induce apoptosis in TNFa-siRNA cells decreased in a similar fashion with decreasing amounts of camptothecin (Supplementary Fig. S1D and E). These results supported the hypothesis that CDIP expression is required for TNFainduced apoptosis.
Endogenous CDIP expression correlates with sensitivity to TNFa-induced apoptosis
If CDIP were acting to sensitize cells to TNFa-mediated apoptosis, we would expect to see some level of endogenous CDIP expression in cancer cells that are inherently sensitive to the antiproliferative effects of TNFa. We obtained a panel of cancer cell lines: a total of 22 human cancer cell lines, including 9 lines with wt-p53 and 13 lines with mutant p53, and investigated whether there was any relationship between Figure 1 . Sensitivity to exogenous/recombinant TNFa-induced apoptosis is dependent upon CDIP. A, IMR90-E1A and U2OS cells were treated with recombinant human TNFa (rhTNFa) for up to 3 days, and viability was assessed by crystal violet staining at the time points indicated. Apoptosis following 2 days of treatment with rhTNFa was determined by TUNEL assay, followed by enumeration of dUTP-fluorescein isothiocyanate (FITC)-positive cells by flow cytometry (FL1-H: dUTP-FITC). B, U2OS-CDIP cells were transfected with control luciferase-(Cont.-) and TNFa-targeting (TNFa-) siRNA for 24 hours, treated with doxycyline (1 mg/mL), and supplemented with either 5 ng/mL recombinant human TNFa (rhTNFa) or an equivalent amount of bovine serum albumin. Long-term viability was assessed by crystal violet staining 72 hours after drug treatments. TUNEL assay was used to determine apoptosis 2 days following treatments and is shown as the percentage of dUTP-FITC-positive cells AE SEM (n ¼ 3). C, IMR90-E1A cells were transfected as in B and treated with camptothecin (0.5 mmol/L) for 24 hours, and supplemented with either 5 ng/mL recombinant human TNFa (rhTNFa) or an equivalent amount of bovine serum albumin. BSA, bovine serum albumin; dox, doxycycline. endogenous CDIP expression and sensitivity to TNFa-induced death. First, CDIP protein expression levels were evaluated by Western blot analysis ( Fig. 2A) . CDIP was abundantly expressed in most of wt-p53 containing cell lines, including U2OS, HT1080, ME-180, and A172, and lesser amounts in A549, H1975, LS175T, but very little in HCT116 and BT474 ( Fig. 2A) . However, CDIP levels were relatively lower in most of mutant p53 containing cell lines but RD cell line. We then divided several lines from this panel of cells into CDIP little-expressing ( Fig. 2B ) and CDIP-expressing cells (Fig. 2C) , and tested their growth response to rhTNFa after 2 days of treatment. The viability of these cells after treatment with rhTNFa did, in fact, reflect their CDIP status, as rhTNFa exerted a more pronounced antiproliferative effect on cell lines expressing Figure 2 . CDIP expression in various cancer cells correlates with sensitivity to exogenous recombinant TNFa-induced apoptosis. A, endogenous CDIP protein expression was examined in a total of 22 human cancer cell lines grown under normal conditions, by Western blot analysis. b-Actin was used as a loading control. Cell lines were grouped based on p53 status (wt-p53 and mutant p53) as indicated. B and C, cells were treated with recombinant rhTNFa as indicated and long-term viability was assessed by crystal violet staining 48 hours posttreatment. Cell lines are grouped based on CDIP expression (B, low and C, high). The plates were scanned by densitometer and quantitated. Cell viability of each plate was shown by a percentage after the normalization to the control (no TNFa treated). D, the effect of CDIP knockdown in cells sensitive to TNFa death (ME-180 and RD) was assessed by transfection with either control luciferase-(Cont.-) or CDIP-targeting siRNA for 24 hours, followed by treatment with rhTNFa (10 ng/mL). Cell viability up to 3 days post-rhTNFa treatment was determined by trypan blue exclusion and is shown as the mean percent increase in dead cells relative to similarly transfected bovine serum albumin-treated control cells AE SEM (n ¼ 3). E, two TNFa-insensitive cell lines, A549 and SW480, were transfected with either control pcDNA3 empty vector (pcDNA3-EV) or CDIP expressing pcDNA3 constructs, respectively, followed by treatment with rhTNFa (10 ng/mL). Cell viability was determined by trypan blue exclusion and is shown relative to transfected control bovine serum albumin-treated cells. BSA, bovine serum albumin. Fig. 2B and C) . The contribution of CDIP to this effect was directly assessed by knockdown of CDIP in these rhTNFa-sensitive lines, followed by trypan blue staining to measure cell death up to 3 days after treatment. The once sensitive ME-180 and RD cells were rendered insensitive to TNFa killing upon knockdown of endogenous CDIP (Fig. 2D) . Conversely, we introduced CDIP into the TNFa-insensitive A549 and SW480 cell lines by transfection with a CDIP expression vector and measured viability after rhTNFa treatment. CDIP expression lead to an increase in the cell death response of both A549 and SW480 cells to rhTNFa, in comparison with empty vector control-treated cells (Fig. 2E) . These findings lend further support to our hypothesis that CDIP expression correlates with sensitivity to acts to TNFa.
CDIP activates the JNK-dependent TNFa apoptotic pathway
We next investigated the effect of CDIP expression on pathways known to act as conduits of TNFa survival and apoptotic signaling. During the TNFa-mediated survival response, JNK is activated in a transient manner, and activation is terminated within 1 hour of TNFa stimulation (4, 14) . Conversely, during the TNFa-mediated apoptotic response, JNK is activated in a sustained manner, and this sustained JNK activity is known to be required for an apoptotic cell fate (14, 15) . After activation of the CDIP!TNFa pathway, U2OS-CDIP cells showed late JNK phosphorylation (Fig. 3A and Supplementary Fig. S2 ). Moreover, induction of CDIP!TNFa downstream of p53 activation (i.e., in response to DNA damage or induced p53 expression) resulted in a similar pattern of late JNK phosphorylation (Fig. 3B) . Treatment with recombinant human TNFa (rhTNFa) alone (i.e., in the absence of CDIP activation) produced no such late JNK phosphorylation (Supplementary Fig. S2 ). This absence of sustained JNK phosphorylation was observed despite an increase in phosphorylated IkB, indicating that the cells were responsive to rhTNFa. CDIP!TNFa signaling also produced an increase in I-kB phosphorylation, confirming that the TNFa pathway was in fact activated in response to doxycycline-induced CDIP!TNFa signal. Interestingly, when compared with cells treated with rhTNFa alone, cells with CDIP!TNFa had lower FLIP expression (Supplementary Fig. S2 ). Because FLIP is a known NF-kB survival target, we supposed that CDIP might be influencing TNFa survival signaling at the level of NF-kB target gene expression (Supplementary Fig. S2 ).
The effect of CDIP on late JNK phosphorylation was next assessed directly by siRNA-directed knockdown of CDIP. In comparison with control siRNA-treated cells with DNA damage-induced p53!CDIP!TNFa activation, knockdown of CDIP resulted in a block of JNK phosphorylation (Fig. 3C) . The contribution of JNK to the CDIP!TNFa apoptotic signal was determined using a well-established chemical inhibitor of JNK (16) (17) (18) . Pretreatment of U2OS-CDIP cells and IMR90-E1A cells with a JNK-selective inhibitor resulted in a complete block of CDIP-dependent apoptosis ( Fig. 3D and E) . U2OS parental cells were not affected by doxycycline or JNK inhibitor treatments, supporting the conclusion that these effects were specific to CDIP activation and JNK inhibition. In addition, CDIP-induced apoptosis was completely unaffected by pretreatment of cells with other mitogen-activated protein kinase inhibitors (Supplementary Fig. S4 ). Together, these results showed that activation of CDIP!TNFa induces a TNFa apoptotic signal that is dependent upon JNK, which is consistent with previous reports showing that JNK is required for the TNFa apoptotic cell fate decision (13) (14) (15) (16) (17) (18) (19) .
NF-kB target gene expression is influenced by CDIP
To test whether CDIP could influence the NF-kB transcriptional program in response to TNFa treatment, we used the expression PCR arrays to analyze NF-kB target-gene expression under 2 conditions: (i) activation of CDIP!TNFa, which leads to an apoptotic cell fate, and (ii) treatment with rhTNFa alone, which is a condition of cell survival (Supplementary Fig.  S4A ). There were 2 NF-kB targets that displayed differential expression under these conditions. Interleukin-8 (IL-8) was specifically upregulated in response to CDIP!TNFa, whereas TNF receptor associated factor 1 (TRAF1) was specifically upregulated in response to TNFa treatment alone (Supplementary Fig. S4B ). To confirm and expand these results, realtime PCR was carried out for additional NF-kB targets. When CDIP was not expressed, we observed a specific upregulation of some NF-kB targets known to play a role in cell survival, such as SOD2 (Supplementary Fig. S4B ). A sandwich ELISA assay confirmed that the CDIP!TNFa-induced increase in IL-8 transcript also resulted in an increase in secreted IL-8 (Supplementary Fig. S4C ).
Inhibition of ROS and IL-8 impairs TNFa apoptosis downstream of CDIP
In view of the evidence that CDIP!TNFa-induced apoptosis requires JNK, the identification of superoxide dismutase 2 (SOD2) as a survival target was noteworthy. SOD2 is an antioxidant enzyme and known NF-kB target (20, 21 ) that functions to counteract the deleterious effects of intracellular ROS. Because ROS accumulation leads to sustained JNK activity in cells undergoing TNFa-induced apoptosis (22) , it is likely that ROS contributes to the late JNK phosphorylation we observed in cells undergoing CDIP!TNFa-dependent apoptosis. To investigate the role of SOD2 and IL-8 modulation in CDIP!TNFa-dependent apoptosis, we pretreated U2OS-CDIP cells with NAC, a chemical antioxidant and an IL-8 blocking antibody, both alone and in combination. The cells were then assessed for ROS production and apoptosis after inducing CDIP expression. ROS levels were induced under conditions of CDIP expression, an effect that was abrogated by pretreatment with NAC ( Fig. 4A-C) . Although blocking of IL-8 had some ability to attenuate the apoptotic response ( Supplementary Fig. S5 ), blocking ROS completely abrogated apoptosis (Fig. 4D) . As expected for a JNK-dependent apoptotic process, the treatment of cells with NAC produced a pronounced decrease in phosphorylated JNK, despite the presence of a TNFa apoptotic signal (Fig. 4E) . Notably, cells that are refractory to TNFa-induced apoptosis showed no detectable levels of phosphorylated JNK (Fig. 4E) . Together, these results showed a primary role for ROS in CDIP!TNFa-dependent apoptosis, accounting for the sustained JNK activation and JNK dependency of this apoptotic response. To further determine whether ROS production was linked to SOD2, we first asked whether SOD2 protein expression changed with CDIP expression and found that SOD2 protein levels were inversely correlated with CDIP expression (Fig. 5A) . Moreover, SOD2 activity was protective against CDIP-induced apoptosis ( Fig. 5B and C) . Overall, this suggests a CDIP!TNFa-dependent apoptotic pathway that involves ROS generation via suppression of the antioxidant SOD2.
TNFa limits the growth of CDIP-positive tumors in vivo
In our previous screen, we identified various tumor cell lines that either displayed high levels of endogenous CDIP expression or no detectable levels of CDIP expression (Fig. 2B and C) . Using 2 such cell lines, we examined the ability of TNFa to limit tumor growth using an in vivo mouse tumor xenograft model. Athymic mice were given subcutaneous injections of RD (positive for CDIP expression) and A549 (negative for CDIP expression) cells. Once the tumors had reached a significant size, rhTNFa was administered by intraperitoneal injection every 5 days, and tumor growth was monitored for up to 3 weeks. After 16 days, the growth of RD tumors in mice given rhTNFa injections was significantly lower compared with control-treated mice. Conversely, the growth of A549 tumors was not significantly different between mice treated with and without rhTNFa (Fig. 6A and B) . These data lend further support to our hypothesis that CDIP sensitizes cancer cells to TNFa-mediated apoptosis and suggests that TNFa may be effective in limiting the growth of CDIP-positive tumors in vivo.
Discussion
The TNFa cell fate decision making process is not completely understood. Although the survival arm of this pathway is well characterized and known to require NF-kB upregulation of prosurvival target genes, and the termination of a JNK-dependent proapoptotic signal, less is known about the apoptotic arm. In this study, we identified CDIP as a key sensitizing factor to TNFa-mediated apoptosis in various cancer cells. We provided evidence that cells with endogenous CDIP expression were inherently sensitive to TNFa-induced death; conversely, cells that have no or little detectable basal CDIP expression were refractory to TNFa killing in vitro and in vivo.
Our analysis of NF-kB target gene expression showed that a program of survival gene expression (i.e., SOD2, TRAF1, A1, and c-IAP1 and 2) is activated when TNFa has no apoptotic effect and that an alternate proapoptotic program, involving the upregulation of IL-8 (23) and the attenuated induction of survival targets is activated when TNFa induces apoptosis. This is consistent with a previous report showing that NF-kBdependent TRAF and c-IAP expression virtually disappears in cells rendered susceptible to TNFa-induced apoptosis by the expression of an I-kB super repressor (24) . In addition, we found that CDIP!TNFa-induced apoptosis is associated with late JNK phosphorylation and that JNK activity is required for this proapoptotic TNFa signal. Given these results, the identification of SOD2 as an NF-kB survival target was particularly interesting. SOD2 is an antioxidant enzyme responsible for the conversion of superoxide radicals (O 2 -) to H 2 O 2 leading to their eventual elimination through peroxidases, which convert H 2 O 2 to H 2 O. ROS is known to inhibit JNK phosphatases leading to the sustained JNK activation required for TNFainduced death (22) . Our observed upregulation of SOD2 would be expected to lower intracellular ROS, or maintain it at levels below a threshold required for JNK apoptotic activity, and is therefore consistent with a TNFa-mediated survival response.
In addition, a recent study showed a deeper understanding of the cross-talk between NF-kB and p53 showing that p53 significantly contributes to nuclear NF-kB activity induced during S-phase arrest and remarkably also in response to TNFa (11) . The importance of ROS to the CDIP!TNFa-mediated apoptotic response is supported by the observation that treating cells with NAC, a chemical antioxidant, resulted in an almost complete block of CDIP-dependent apoptosis, and an attenuation of JNK phosphorylation. Furthermore, if ROS is critical for tipping the balance in favor of TNFa-mediated apoptosis in CDIP expressing cells over survival in CDIP lesser expressing cells treated with rhTNFa, we would expect to see some difference in intracellular ROS levels between these conditions. Indeed, cells undergoing CDIP!TNFa-mediated apoptosis showed elevated ROS levels compared with CDIP nonexpressing cells that survived in response to TNFa. Figure 5 . CDIP expression correlates with a decrease in SOD2 expression, and SOD2 expression inhibits CDIP-dependent cell death. A, SOD2 protein levels were assessed by Western blot analysis in U2OS-CDIP cells (AE doxycycline, transfected with siCont or siCDIP RNA or with/without rhTNFa treatment). B, U2OS-CDIP cells were cultured with/without doxycycline in the presence of rhTNFa. SOD2/Mn SOD activity assay was carried out as suggested by vendor (Millipore Inc: HCS232). C, the SOD2 open reading frame with an amino-terminus HA tag was cloned into pcDNA4 and then introduced into U2OS cells along with empty vector (EV) pcDNA4, which served as a control. Sequential Western blot analysis was carried out with anti-HA and anti-SOD2 antibodies (Santa Cruz) to detect exogenous SOD2 protein expression. U2OS-CDIP cells were transfected with a pcDNA4-SOD2 (SOD2) expression vector or empty pcDNA4 vector as a control (EV), and 24 hours posttransfection, the cells were treated with doxycycline to activate CDIP expression. Viability was assessed with crystal violet staining and apoptosis was determined using TUNEL assay followed by FACS enumeration of TUNEL-positive cells and is shown as an increase in the TUNEL-positive population relative to cells that were left untreated (doxycycline). dox, doxycycline.
Together, these results extend our previous work that identified a novel CDIP!TNFa proapoptotic pathway acting downstream of p53 (13) and provide an explanation for why cells with an activated CDIP!TNFa signal follow an apoptotic cell fate. In our current model (Fig. 6C) , NF-kB survival gene expression downstream of TNFa is suppressed in CDIP expressing cells in favor of IL-8 expression, which allows the apoptotic cell fate to prevail. Conversely, cells that do not express CDIP respond to TNFa by activating a program of NF-kB survival target gene expression. In particular, SOD2 acts to maintain intracellular ROS levels below a threshold required for JNK activation and apoptosis, although other NF-kB survival targets also likely contribute to this survival cell fate. Deregulated TNFa signaling contributes to a number of disease pathologies (i.e., cancer, sepsis, diabetes, and autoimmune disease); therefore, identifying factors that modulate TNFa cell fate decision making is of great therapeutic value. To this end, we are currently employing a chemical genetic approach to identify CDIP activators and suppressors.
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